Search
Ozagrel
go.drugbank.com/drugs/DB12017InvestigationalOzagrel has been used in trials studying the treatment of Dry Eye Syndromes.
Beclabuvir
go.drugbank.com/drugs/DB12225InvestigationalBeclabuvir has been used in trials studying the treatment of Hepatitis C, Chronic.
Isoquinoline, 7-(2-(3,6-dihydro-4-(3-(trifluoromethyl)phenyl)-1(2h)-pyridinyl)ethyl)-
go.drugbank.com/drugs/DB16204Investigationalthe Reduction of Inflammation in Patients With Active Rheumatoid Arthritis). … Isoquinoline, 7-(2-(3,6-dihydro-4-(3-(trifluoromethyl)phenyl)-1(2h)-pyridinyl)ethyl)- is under investigation in clinical trial NCT00545454 (Activity and Safety of Oral Administration of SSR150106XB for
Sovleplenib
go.drugbank.com/drugs/DB17557InvestigationalIt is under investigation in clinical trial NCT03483948 (Phase I Study of Hmpl-523+azacitidine in Elderly Patients With Acute Myeloid Leukemia).
Alpibectir
go.drugbank.com/drugs/DB21561InvestigationalAlpibectir is under investigation in clinical trial NCT06748937 (A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide).
Ceperognastat
go.drugbank.com/drugs/DB21591InvestigationalCeperognastat is under investigation in clinical trial NCT05063539 (A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease).
Ranosidenib
go.drugbank.com/drugs/DB21727InvestigationalRanosidenib is under investigation in clinical trial NCT06387069 (A Study to Evaluate HMPL-306 in Patients With IDH1- and IDH2-mutated Acute Myeloid Leukemia).
N-(carboxycarbonyl)-D-phenylalanine
go.drugbank.com/drugs/DB08263ExperimentalN-(carboxycarbonyl)-D-phenylalanine is a solid. This compound belongs to the n-acyl-alpha amino acids. … These are compounds containing an alpha amino acid which bears an acyl group at its terminal nitrogen atom. It targets the protein hypoxia-inducible factor 1-alpha inhibitor.
Synonyms: N-(carboxycarbonyl)-D-phenylalaninePamufetinib
go.drugbank.com/drugs/DB20752InvestigationalThe usage of the INN stem '-tinib' in the name indicates that Pamufetinib is a tyrosine kinase inhibitor. Pamufetinib is under investigation in clinical trial NCT04999761 (AB122 Platform Study).